North America Pulmonary Arterial Hypertension Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Drugs [Endothelin Receptor Antagonists (ERAs), Prostacyclin and Prostacyclin Analogs, sGC Stimulators, and pde-5 Dipsticks], Type (Branded a

North America Pulmonary Arterial Hypertension Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Drugs [Endothelin Receptor Antagonists (ERAs), Prostacyclin and Prostacyclin Analogs, sGC Stimulators, and pde-5 Dipsticks], Type (Branded and Generics), Route of Administration (Oral, Intravenous/Subcutaneous, and Inhalational), and Distribution Channel (Hospital Pharmacies and Clinics, Online Pharmacies, and Retail Pharmacies)

The North America pulmonary arterial hypertension market is expected to grow from US$ 3,147.76 million in 2022 to US$ 4,456.90 million by 2028; it is estimated to grow at a CAGR of 6.0% from 2022 to 2028.

Rising Approvals of Pulmonary Arterial Hypertension Drugs Drives North America Pulmonary Arterial Hypertension Market

In November 2021, the US Food and Drugs Administration (FDA) granted tentative approval for Yutrepia (treprostinil) inhalation powder. Yutrepia is indicated to treat PAH to improve exercise ability in adult patients with New York Heart Association (NYHA) Functional Class II-III symptoms. In July 2021, The Janssen Pharmaceutical Companies of Johnson & Johnson received the FDA’s approval for UPTRAVI (selexipag) injection for intravenous (IV) to treat pulmonary arterial hypertension (PAH, WHO Group I) in adult patients with WHO functional class (FC) II–III. These patients are temporarily unable to take oral therapy. Similarly, in August 2021, Aerami Therapeutics, Inc. announced that the FDA granted the company an orphan drug designation for imatinib to treat PAH patients. AER–901, a drug-device combination product candidate for inhaled imatinib for the treatment of PAH, completed its Phase 1 trial in 2021. Aerami plans to advance AER-901 into a Phase 2 trial by the first half of 2023, following an amendment to the open AER-901 IND application with the FDA.

In September 2020, Alembic Pharmaceuticals Limited announced that its subsidiary Alembic Global Holdings SA received tentative FDA approval for its Abbreviated New Drugs Application (ANDA) Treprostinil Injection is administered in 20-mL multidose vials in five strengths, containing 50 mg, 20 mg, 100 mg, and 200 mg (2.5 mg/mL, 1 mg/mL, 5 mg/mL, and 10 mg/mL) of treprostinil, respectively. In May 2022, United Therapeutic Corporation received FDA approval for Tyvaso DPI (treprostinil) inhalation powder to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) and pulmonary arterial hypertension (PAH; WHO Group 1) to enhance exercise ability.

Thus, the rising number of pulmonary arterial hypertension drug approvals is boosting the growth of the North America pulmonary arterial hypertension market .

North America Pulmonary Arterial Hypertension Market Overview

The North America pulmonary arterial hypertension market is segmented into the US, Canada, and Mexico. The market growth in this region is attributed due to a surge in health expenditure, the high prevalence of pulmonary arterial hypertension, and a rise in initiatives by the government and manufacturers. The US pulmonary arterial hypertension market holds a significant share in North America. The rising healthcare expenditure is fueling the drug development of pulmonary arterial hypertension (PAH). According to US Centers for Medicare & Medicaid Services, the national healthcare expenditure in the US increased by 9.7% in 2019 and reached US$ 4.1 trillion in 2020. Furthermore, as per the same source, national health spending is expected to grow at a 5.4% annual rate from 2019 to 2028, and it is expected to reach US$ 6.2 trillion by 2028. The rising healthcare expenditure is estimated to increase the research and development of PAH drugs due to the availability of limited drugs in the market for treating PAH.

According to the American Lung Association, PAH is a rare and progressive disorder that accounts for ~500-1000 new cases being diagnosed each year in the US. Additionally, as per the same source, approximately 15-20% of PAH patients are suffering from heritable PAH, which is caused by genetic mutations. Further, manufacturers are taking various initiatives to provide information and resources to healthcare practitioners, fueling the market growth. For instance, the PAH Initiative, supported by United Therapeutics, provides resources and information to assist healthcare providers in treating patients impacted by PAH. Thus, the rising cases of PAH diagnosed each year and initiatives undertaken by drug manufacturers fuel the demand for pulmonary arterial hypertension drugs and other treatment methods, further bolstering the pulmonary arterial hypertension market growth in the US.

North America Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (US$ Million)

North America Pulmonary Arterial Hypertension Market Segmentation

The North America pulmonary arterial hypertension market is segmented on the basis of drugs, type, route of administration, distribution channel, and country.

Based on drugs, the North America pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. In 2022, the prostacyclin and prostacyclin analogs segment registered the largest share in the North America pulmonary arterial hypertension market.

Based on type, the North America pulmonary arterial hypertension market is bifurcated into branded and generics. In 2022, the branded segment registered a larger share in the North America pulmonary arterial hypertension market.

Based on route of administration, the North America pulmonary arterial hypertension market is segmented into oral, intravenous/subcutaneous, and inhalational. In 2022, the oral segment registered the largest share in the North America pulmonary arterial hypertension market.

Based on distribution channel, the North America pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies. In 2022, the hospital pharmacies and clinics segment registered the largest share in the North America pulmonary arterial hypertension market.

Based on country, the North America pulmonary arterial hypertension market is segmented into the US, Canada, and Mexico. In 2022, the US registered the largest share in the North America pulmonary arterial hypertension market.

Aerami Therapeutics Holdings Inc, Bayer AG, Gilead Sciences Inc, GSK Plc, Johnson & Johnson, Lupin Ltd, Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd, and United Therapeutics Corp are the leading companies operating in the North America pulmonary arterial hypertension market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America pulmonary arterial hypertension market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the North America pulmonary arterial hypertension market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the pulmonary arterial hypertension market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution